Physiomics PLC Conference presentation
April 09 2021 - 8:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
09 April 2021
9 April 2021
Physiomics plc
("Physiomics") or ("the Company")
Conference presentation
Physiomics to present on Personalized Medicine and Virtual
Tumour at AACR 2021 Annual Meeting
Physiomics plc (AIM: PYC), a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry, is pleased to announce that it is
participating in the American Academy of Cancer Research ("AACR")
Annual Meeting 2021, being held as a virtual event.
The Company will be presenting two original posters in the
session "PO.BSB02.03.- Mathematical Modelling", scheduled for 10
April 2021 at 8.30 a.m. - 11.59 p.m. EDT (Eastern Daylight Time).
The posters are titled:
-- "A precision dosing application for patients treated with
docetaxel and G-CSF" (Abstract #228) and
-- "The abscopal effect: modelling and predicting the effect of
radiation therapy on non-irradiated tumour when combined with
immune checkpoint blockers" (Abstract #232)
The session will include live interactions and the posters will
remain available for viewing by registered attendees until Monday
the 21(st) of June 2021.
As previously disclosed, the Company is developing a
personalised dosing tool to support clinician decision making on
dosing of docetaxel in prostate cancer. The precision dosing poster
describes additional functionality that has been incorporated to
model the co-administration of G-CSF (a prophylactic treatment for
neutropenia). This new functionality should increase the utility of
the tool during the current COVID-19 pandemic when G-CSF is being
more commonly administered than previously.
The second poster describes an update to the Company's Virtual
Tumour(TM) model, enabling the simulation of the effects of
radiotherapy not only on the irradiated tumour but other distant
tumours (the "abscopal effect"). The abscopal effect is mainly
driven by the activation of the immune systems and we illustrate
how it can be synergistic with immune checkpoint blockers.
Copies of the posters will be made available on Physiomics'
website at 8.30 a.m. EDT (1.30 p.m. BST) on 10 April 2021 at:
https://www.physiomics.co.uk/resources .
According to AACR, it is the oldest and largest scientific
organisation in the world, focused on every aspect of high-quality,
innovative cancer research. Its annual conference is usually
attended by representatives from public and private sector
organisations, from the very small to the largest global players,
with over 20,000 participants attending in 2019 (the last in-person
meeting). This year, as a virtual event, access will be free to
everyone who registers, and presentations may therefore reach a
wider audience than usual.
More information about the conference may be found using the
following link:
https://www.aacr.org/meeting/aacr-annual-meeting-2021/
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 80 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAZZGGDZLGGMZM
(END) Dow Jones Newswires
April 09, 2021 09:00 ET (13:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2023 to Apr 2024